Modular Bioprocessing System for CAR-T Cell Manufacturing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing bioprocessing systems for manufacturing CAR-T cell therapies are complex, costly, and inflexible, with high human touchpoints that increase contamination risks and workflow bottlenecks, limiting their adaptability and ease of use.
Innovation Solution
A modular bioprocessing system with automated modules for enrichment, activation, genetic modification, and expansion, utilizing disposable kits and magnetic cell isolation techniques to streamline processes, reduce manual interventions, and enhance scalability and flexibility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional bioprocessing systems are used for CAR-T cell manufacturing, then cell production can be achieved, but the systems require many complex operations with large number of human touchpoints, increasing contamination risk and reducing efficiency
Solution Approach 1:
The bioprocessing system is divided into separate functional modules (enrichment module, activation module, transduction module, expansion module) that can operate independently. Each module handles specific operations, reducing the need for manual intervention between steps and minimizing contamination risk while maintaining production capability.
Solution Approach 2:
The system incorporates automated cell processing capabilities where the bioreactor and associated modules perform operations without human intervention. The automated system manages cell enrichment, activation, transduction, and expansion autonomously, eliminating human touchpoints that would increase contamination risk.
2Reliability
If automated bioprocessing systems are implemented to reduce human touchpoints, then contamination risk decreases, but the systems become very costly and inflexible
Solution Approach 1:
By segmenting the system into discrete, standardized modules, the patent enables flexible reconfiguration for different cell therapy protocols while maintaining automated operation. Each module can be independently optimized or replaced, providing adaptability without requiring complete system redesign, thus avoiding high costs associated with fully customized automated systems.
Solution Approach 2:
The modular architecture allows the same automated system to perform multiple cell therapy manufacturing processes through reconfiguration of modules. The universal interface and standardized protocols enable the system to adapt to different cell types, vectors, and processing requirements, providing flexibility comparable to manual systems while maintaining automation benefits.
3Productivity
If complex automated systems are used to streamline bioprocessing, then manufacturing efficiency improves, but the systems require customers to adapt their processes to particular equipment, reducing ease of use
Solution Approach 1:
The system employs universal interfaces and standardized operating protocols across all modules, allowing customers to implement their preferred cell therapy processes without adapting to proprietary equipment requirements. The modular design supports multiple processing workflows, enabling high manufacturing efficiency while maintaining ease of use through familiar, flexible process implementation.
Solution Approach 2:
The system incorporates dynamic control capabilities that automatically adjust processing parameters based on real-time measurements and pre-programmed protocols. This dynamic adaptation allows the automated system to handle varied cell therapy processes efficiently without requiring manual reconfiguration, maintaining both high productivity and ease of operation.
4Adaptability or versatility
If manual operations are used in bioprocessing, then process flexibility is maintained, but the number of human touchpoints increases, adding time to manufacturing and increasing contamination risk
Solution Approach 1:
The patent divides the bioprocessing workflow into discrete modular steps that can be automatically executed. Each module handles a specific function (enrichment, activation, transduction, expansion), enabling automated high-throughput processing while maintaining the flexibility to customize individual module operations for different cell therapy protocols.
Solution Approach 2:
The automated modular system enables continuous processing where cell material flows sequentially through enrichment, activation, transduction, and expansion modules without interruption or manual handling. This continuous automated workflow eliminates the time losses associated with manual operations while maintaining process flexibility through programmable control of each stage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modular system improves efficiency, reduces contamination risks, and increases adaptability by allowing parallel processing of multiple samples, enhancing equipment utilization and overall manufacturing efficiency while maintaining product consistency and safety.
Implementation Method 1
the cells may be activated using magnetic beads coated with anti-CD3/anti-CD28 monoclonal antibodies or cell-based artificial antigen presenting cells (aAPCs), which can be removed from the culture using magnetic separation
Implementation Method 2
The first step in the production of CAR-T cells involves using apheresis, e.g., leukocyte apheresis, to remove blood from a patient's body and separate the leukocytes
Data Source
AI summary
A method for bioprocessing includes the steps of providing a bioprocessing system having a first bioreactor vessel and a second bioreactor vessel, activating a population of cells in the first bioreactor vessel, genetically modifying the population of cells to produce a population of genetically modified cells, and expanding the population of genetically modified cells within the first bioreactor vessel and the second bioreactor vessel.